US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
GB9423910D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
AU738675B2
(en)
|
1997-11-12 |
2001-09-20 |
Bayer Intellectual Property Gmbh |
2-phenyl-substituted imidazotriazinones as phosphodiesterase inhibitors
|
AU2641199A
(en)
*
|
1998-02-27 |
1999-09-15 |
Kyowa Hakko Kogyo Co. Ltd. |
Remedies for erectile dysfunction
|
WO1999059584A1
(en)
*
|
1998-05-20 |
1999-11-25 |
Schering Corporation |
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
|
EP0967284A1
(en)
*
|
1998-05-28 |
1999-12-29 |
Pfizer Limited |
Phosphodiesterases
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
JP2000178204A
(ja)
*
|
1998-10-05 |
2000-06-27 |
Eisai Co Ltd |
ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
|
CA2346350C
(en)
|
1998-10-05 |
2008-01-08 |
Eisai Co., Ltd. |
Intraoral quickly disintegrating tablets
|
JP2000191518A
(ja)
*
|
1998-10-19 |
2000-07-11 |
Eisai Co Ltd |
溶解性の改善された口腔内速崩壊性錠剤
|
UA67802C2
(uk)
*
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
EP1161255A4
(en)
*
|
1999-03-08 |
2002-07-17 |
Merck & Co Inc |
METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
US6451807B1
(en)
*
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
HUP0001632A3
(en)
*
|
1999-04-30 |
2001-12-28 |
Lilly Icos Llc Wilmington |
Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
|
CA2365782A1
(en)
*
|
1999-04-30 |
2000-11-09 |
William E. Pullman |
Treatment of female arousal disorder
|
IL147641A0
(en)
*
|
1999-08-03 |
2002-08-14 |
Lilly Icos Llc |
Beta-carboline pharmaceutical compositions
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
GB9922124D0
(en)
*
|
1999-09-17 |
1999-11-17 |
Pfizer Ltd |
Phosphodiesterase enzymes
|
US6436944B1
(en)
*
|
1999-09-30 |
2002-08-20 |
Pfizer Inc. |
Combination effective for the treatment of impotence
|
CN1378547A
(zh)
|
1999-10-11 |
2002-11-06 |
辉瑞大药厂 |
用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4,3-d]嘧啶-7-酮类化合物
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
UA74826C2
(en)
*
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
WO2001094345A2
(en)
*
|
2000-06-07 |
2001-12-13 |
Lilly Icos Llc |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
EP1289990A1
(en)
*
|
2000-06-08 |
2003-03-12 |
Lilly Icos LLC |
Tetracyclic diketopierazine compounds as pdev inhibitors
|
ATE330958T1
(de)
*
|
2000-06-23 |
2006-07-15 |
Lilly Icos Llc |
Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
|
CA2413510C
(en)
|
2000-06-26 |
2007-12-11 |
Lilly Icos Llc |
Condensed pyrazindione derivatives
|
CA2423357C
(en)
|
2000-08-02 |
2008-05-27 |
Lilly Icos Llc |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
EP1316316B1
(en)
*
|
2000-09-06 |
2012-04-04 |
Mitsubishi Tanabe Pharma Corporation |
Preparations for oral administration
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
DE60111553T2
(de)
*
|
2000-10-02 |
2006-04-06 |
Lilly Icos Llc, Wilmington |
Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
|
AU2001296699A1
(en)
|
2000-11-08 |
2002-05-21 |
Lilly Icos Llc |
Condensed pyrazindione derivatives as pde inhibitors
|
CN100372536C
(zh)
*
|
2001-02-15 |
2008-03-05 |
田边三菱制药株式会社 |
在口腔中迅速崩解的片剂
|
DE10118305A1
(de)
*
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Zusammensetzungen zur nasalen Applikation
|
WO2002083631A1
(en)
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
WO2002098877A1
(en)
*
|
2001-06-05 |
2002-12-12 |
Lilly Icos Llc |
Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
|
AR036674A1
(es)
*
|
2001-08-28 |
2004-09-29 |
Schering Corp |
Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
JP2005509038A
(ja)
*
|
2001-11-09 |
2005-04-07 |
シェーリング コーポレイション |
多環式グアニン誘導体ホスホジエステラーゼv阻害剤
|
JP4484517B2
(ja)
|
2001-11-14 |
2010-06-16 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
ホスホジエステラーゼ阻害剤として有用な置換された四環式ピロロキノロン誘導体
|
JP4554931B2
(ja)
|
2001-12-20 |
2010-09-29 |
メルク セローノ ソシエテ アノニム |
プロスタグランジン調節物質としてのピロリジン誘導体
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
DE10232113A1
(de)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
AU2003257289A1
(en)
|
2002-07-26 |
2004-02-16 |
Kenneth W. Adams |
Pharmaceutical compositions for penis enlargement
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
KR101292492B1
(ko)
|
2004-05-11 |
2013-08-01 |
이모셔널 브레인 비.브이. |
약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
|
US20060235005A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Oak Labs, Corp. |
Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
BRPI0615972A2
(pt)
|
2005-07-29 |
2011-05-31 |
Concert Pharmaceuticals Inc |
composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
WO2007025177A2
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
CA2622200A1
(en)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
MX2008006076A
(es)
|
2005-11-09 |
2008-12-16 |
Combinatorx Inc |
Metodos, composiciones y kits para el tratamiento de condiciones medicas.
|
EP1790343A1
(en)
|
2005-11-11 |
2007-05-30 |
Emotional Brain B.V. |
Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
JP2009536669A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
アンジオテンシン調節による神経新生
|
EP2026813A2
(en)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
CN101500572B
(zh)
*
|
2006-07-07 |
2013-08-21 |
特瓦制药工业有限公司 |
包含他达拉非和至少一种载体的固体组合物
|
BRPI0716604A2
(pt)
|
2006-09-08 |
2013-04-09 |
Braincells Inc |
combinaÇÕes contendo um derivado de 4-acilaminopiridina
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP1925307A1
(en)
|
2006-11-03 |
2008-05-28 |
Emotional Brain B.V. |
Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
CN101674728A
(zh)
|
2007-02-12 |
2010-03-17 |
Dmi生物科学公司 |
降低曲马多的副作用
|
KR20150089085A
(ko)
*
|
2007-02-12 |
2015-08-04 |
브릭스 파마슈티컬스 인코퍼레이티드 |
조루 및 발기부전을 동시에 치료하는 방법
|
MX2009011588A
(es)
*
|
2007-04-25 |
2009-11-05 |
Teva Pharma |
Formas de dosificacion solidas que comprenden tadalafil.
|
DE102007028869A1
(de)
*
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
WO2009091777A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
WO2009135179A2
(en)
|
2008-05-02 |
2009-11-05 |
Gilead Sciences, Inc. |
The use of solid carrier particles to improve the processability of a pharmaceutical agent
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
AR073522A1
(es)
|
2008-09-30 |
2010-11-10 |
Biolab Sanus Farmaceutica Ltda |
Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
JP6074142B2
(ja)
|
2009-02-26 |
2017-02-01 |
タール ファーマシューティカルズ,インコーポレイテッド |
医薬化合物の結晶化
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
*
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
UY33535A
(es)
*
|
2010-08-13 |
2011-12-01 |
Biolab Sanus Farmaceutuca Limitada |
Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
|
KR20200003245A
(ko)
|
2011-10-14 |
2020-01-08 |
어레이 바이오파마 인크. |
선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
|
US20150119399A1
(en)
|
2012-01-10 |
2015-04-30 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
MX357741B
(es)
*
|
2012-07-06 |
2018-07-23 |
Laboratorios Senosiain S A De C V Star |
Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
|
EP2903619B1
(en)
|
2012-10-05 |
2019-06-05 |
Robert I. Henkin |
Phosphodiesterase inhibitors for treating taste and smell disorders
|
US9695174B2
(en)
*
|
2013-10-07 |
2017-07-04 |
Millennium Pharmaceuticals, Inc. |
Inhibitor of breast cancer resistance protein (BCRP)
|
CN106233141B
(zh)
|
2014-02-18 |
2018-08-21 |
罗伯特·I·汉金 |
用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
|
JP6687550B2
(ja)
|
2014-06-23 |
2020-04-22 |
セルジーン コーポレイション |
肝疾患又は肝機能異常を治療するためのアプレミラスト
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
WO2018112258A1
(en)
|
2016-12-14 |
2018-06-21 |
Respira Therapeutics, Inc. |
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
|
HUE052118T2
(hu)
|
2018-01-10 |
2021-04-28 |
Gap S A |
Tadalafil szuszpenziót tartalmazó lágy zselatinkapszulák
|
US11348670B2
(en)
|
2018-06-14 |
2022-05-31 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|